The impact of age on the diagnosis and therapy of myelodysplastic syndromes: Results from a retrospective multicenter analysis in Germany

European Journal of Haematology

Volumn 91, Issue 6, 2013, Pages 473-482

  Gattermann, Norbert ^a   Kündgen, Andrea ^a   Kellermann, Lenka ^b   Zeffel, Matti ^c   Paessens, Bernadette ^c   Germing, Ulrich ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Oncology Information Service   (Germany)

^c Celgene GmbH   (Germany)

Author keywords

Diagnosis; Elderly; Myelodysplastic syndromes; Prognosis; Therapy

Indexed keywords

ANTHRACYCLINE; AZACITIDINE; BUSULFAN; CYCLOSPORIN A; CYTARABINE; FLUDARABINE; HYDROXYUREA; LENALIDOMIDE; MERCAPTOPURINE; THALIDOMIDE; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; AGE; ALLOTRANSPLANTATION; ARTICLE; CHROMOSOME ANALYSIS; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL DECISION MAKING; COMORBIDITY; ERYTHROCYTE TRANSFUSION; FEMALE; GERMANY; HOSPITAL PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; PATIENT CARE; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; RISK ASSESSMENT;

DIAGNOSIS; ELDERLY; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; THERAPY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BLOOD TRANSFUSION; COMORBIDITY; CYTOGENETIC ANALYSIS; DECISION MAKING; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; YOUNG ADULT;

EID: 84888070511     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12196     Document Type: Article

References (39)

1. Mufti GJ. Pathobiology, classification, and diagnosis of myelodysplastic syndrome. Best Pract Res Clin Haematol 2004;17:543-57.
2. Cazzola M, Malcovati L. Myelodysplastic syndromes - coping with ineffective hematopoiesis. N Engl J Med 2005;352:536-8.
3. Brunning RD, Orazi A, Germing U, LeBeau MM, Porwit A, Baumann I, Vardiman JW, Hellstrom-Lindberg E. Myelodysplastic syndromes/neoplasms, overview. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, eds. WHO classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. Lyon: IARC Press; 2008:88-107.
4. Strupp C, Gattermann N, Aul C, Haas R, Germing U. Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry. Leuk Res 2011;35:1591-6.
5. Germing U, Strupp C, Giagounidis A. Clinical features and prognosis of patients with myelodysplastic syndromes. Cancer Treatment Rev 2007;33:S15-8.
6. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes. Incidence and survival in the United States. Cancer 2007;109:1536-42.
7. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 2007;25:1908-15.
8. Ria R, Moschetta M, Reale A, Mangialardi G, Castrovilli A, Vacca A, Dammacco F. Managing myelodysplastic symptoms in elderly patients. Clin Interv Aging 2009;4:413-23.
9. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352:549-57.
10. List A, Dewald G, Bennett J, et al. ; for the Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:1456-65.
11. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. ; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223-32.
12. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galtoin DA, Gralnick HR, Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-99.
13. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
14. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503-3510.
15. Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008;113:1351-61.
16. Germing U, Hildebrandt B, Pfeilstöcker M, et al. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 2005;19:2223-31.
17. Nösslinger T, Tüchler H, Germing U, et al. Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Ann Oncol 2010;21:120-5.
18. Sperr WR, Wimazal F, Kundi M, Baumgartner C, Nösslinger T, Makrai A, Stauder R, Krieger O, Pfeilstöcker M, Valent P. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol 2010;21:114-9.
19. Sorror ML, Sandmaier BM, Storer BE, Maris MB, Baron F, Maloney DG, Scott BL, Deeg HJ, Appelbaum FR, Storb R. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007;25:4246-54.
20. Della Porta MG, Malcovati L, Strupp C, et al. MDSCI: risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica 2011;96:441-9.
21. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454-65.
22. Sekeres MA, Schoonen WM, Kantarjian H, List A, Fryzek J, Paquette R, Maciejewski JP. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst 2008;100:1542-51.
23. Kelaidi C, Stamatoullas A, Beyne-Rauzy O, et al. ; Groupe Francophone des Myélodysplasies. Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies. Haematologica 2010;95:892-9.
24. Executive Committee of the German Medical Association on the recommendation of the Scientific Advisory Board Cross-sectional guidelines for therapy with blood components and plasma derivates - 4th revised revision. Transfus Med Hemothe 2009;36:345-492.
25. Guidelines on MDS of the German Society of Hematology and Oncology (DGHO). Available at: http://www.dgho.de/onkopedia/MDS (accessed 25 January 2011).
26. NCCN Clinical Practice Guideline in Oncology. Myelodysplastic Syndromes. Version 2.2011. Available at: www.nccn.org (accessed 12 August 2011).
27. Schanz J, Tüchler H, Solé F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012;30:820-9.
28. ®): an EPIC study post-hoc analysis. Leuk Res 2011;35(Suppl 1):136-7.
29. ®) in Patients with Low/Intermediate-1 Risk MDS and Transfusional Iron Overload. Blood 2009;114: Abstract 4854.
30. Meerpohl JJ, Antes G, Rücker G, Fleeman N, Motschall E, Niemeyer CM, Bassler D. Deferasirox for managing iron overload in people with myelodysplastic syndrome. Cochrane Database Syst Rev 2010; Art. No.: CD007461, doi:10.1002/14651858.CD007461.pub2
31. Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011;118:3765-3776.
32. Le Bras F, Sebert M, Kelaidi C, et al. Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion - the GFM experience. Leuk Res 2011;35:1444-8.
33. Klärner V. Analysis of treatment choices and outcome for MDS and AML patients 60 years and older from the university of Düsseldorf. Leuk Res 2011;35(Suppl 1): Abstract 93.
34. Powers A, Stein K, Knoth RL, Broder M, Chang E. Health care utilization and costs in patients with early onset myelodysplastic syndrome in a commercially insured population. J Clin Oncol 2011;29(Suppl): Abstract 6552.
35. Rohrbacher M, Hasford J. Epidemiology of chronic myeloid leukaemia (CML). Best Pract Res Clin Haematol 2009;22:3295-302.
36. Kellermann L, Arnold D, Al-Batran S-E, Schmoll H-J. Did the uptake of new treatment options change the treatment strategy in patients with colorectal cancer and primary non-resectable metastases? The results of large population-based survey in Germany 2005-2007 Annual European Congress of the International Society for Pharmacoeconomics and Outcome Research (ISPOR) 2010; Poster PCN25.
37. Seymour JF, Fenaux P, Silverman LR, et al. Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 2010;76:218-27.
38. Sanna A, Cannella L, Gozzini A, Breccia M, Sassolini F, Bosi A, Alimena G, Santini V. Comorbidities indexes in patients treated with 5-azacitidine are a an useful and easily applicable tool to refine prognostic evaluation. Blood 2010;116: Abstract 606.
39. Sanna A. Comorbidities influence prognosis in MDS High-risk patients treated with 5-azacitidine. Haematologica 2011;96(Suppl 2):444p.